(AOF) – Transgene displays 15.7 million euros of available cash as of December 31, 2023, compared to 26.8 million euros at the end of 2022, which gives it financial visibility until the fourth quarter of 2025. The biotech which designs and develops immunotherapies against cancer based on viral vectors shows a net loss of 22.3 million euros in 2023, compared to a net loss of 32.8 million euros in 2022. “In 2023, Transgene crossed important steps,” says CEO Alessandro Riva.
“We have obtained decisive data, which confirms the value and potential of our innovative immunotherapies to fight cancer,” he adds.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
